The concern of generic challenges has long loomed above copyright’s iconic drug, Viagra, triggering questions about the prospects of related medicinal investments. While first times saw substantial returns, the patent expiration has opened the way for discounted copies, possibly lowering revenue and presenting a genuine danger for investors looki